CTMX financials
CytomX Therapeutics (CTMX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
CTMX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $76.20M | $76.20M | -$22.36M | -$17.37M | -0.15 |
| 2024 | $138.10M | $138.10M | $25.00M | $31.87M | 0.38 |
| 2023 | $101.21M | $101.21M | -$6.48M | -$569.00K | -0.01 |
| 2022 | $53.16M | $53.16M | -$101.33M | -$99.32M | -1.48 |
| 2021 | $37.31M | $37.31M | -$116.04M | -$115.87M | -1.26 |
| 2020 | $68.43M | $68.43M | -$80.54M | -$64.82M | -0.71 |
- CTMX revenue was $76.20M in fiscal 2025, net income -$17.37M.
Updated 2026-11-02 17:54 UTC